New combo therapy aims to stall liver cancer progression

NCT ID NCT05620771

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for adults with advanced liver cancer (hepatocellular carcinoma) that is hard to treat. It compares two standard drug regimens — immunotherapy (atezolizumab + bevacizumab) or targeted pills (lenvatinib or cabozantinib) — given after a liver-directed radiation treatment called Therasphere (Y-90). The goal is to see which combination better delays cancer growth. About 200 participants will be enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Northwestern Medicine Delnor Hospital

    RECRUITING

    Geneva, Illinois, 60134, United States

    Contact Email: •••••@•••••

  • Northwestern Medicine Grayslake Outpatient Center

    RECRUITING

    Grayslake, Illinois, 60030, United States

    Contact Email: •••••@•••••

  • Northwestern Medicine Kishwaukee Hospital

    RECRUITING

    DeKalb, Illinois, 60115, United States

    Contact Email: •••••@•••••

  • Northwestern Medicine Lake Forest Hospital

    RECRUITING

    Lake Forest, Illinois, 60045, United States

    Contact Email: •••••@•••••

  • Northwestern Medicine Orland Park

    RECRUITING

    Orland Park, Illinois, 60462, United States

    Contact Email: •••••@•••••

  • Northwestern Medicine Warrenville

    RECRUITING

    Warrenville, Illinois, 60555, United States

    Contact Email: •••••@•••••

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.